Comment
doi: 10.7326/ACPJ202106150-067.
Epub 2021 Jun 1.
In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs
Affiliations
- PMID: 34058114
- DOI: 10.7326/ACPJ202106150-067
Item in Clipboard
Comment
In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs
Ann Intern Med.
2021 Jun.
Abstract
Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. 33441402.
Comment on
-
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573. BMJ. 2021. PMID: 33441402 Free PMC article.
Similar articles
-
In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA1c and SBP and may reduce body weight.Ann Intern Med. 2020 Nov 17;173(10):JC52. doi: 10.7326/ACPJ202011170-052. Ann Intern Med. 2020. PMID: 33197349
-
Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.Cardiovasc Diabetol. 2020 Jul 6;19(1):107. doi: 10.1186/s12933-020-01078-5. Cardiovasc Diabetol. 2020. PMID: 32631337 Free PMC article.
-
In T2D, SGLT-2 inhibitor effects on CV and kidney outcomes were consistent regardless of GLP-1 receptor agonist use.Ann Intern Med. 2024 Nov;177(11):JC124. doi: 10.7326/ANNALS-24-02849-JC. Epub 2024 Nov 5. Ann Intern Med. 2024. PMID: 39496174
-
A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.Ann Pharmacother. 2021 Jan;55(1):65-79. doi: 10.1177/1060028020935105. Epub 2020 Jun 22. Ann Pharmacother. 2021. PMID: 32571083
-
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30. Arterioscler Thromb Vasc Biol. 2020. PMID: 31996025 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
